

#3  
2-21-07

JC927 U.S. PTO  
09/699003  
10/26/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. Rigdon Lentz

Serial No.: Continuation of 09/316,226 Art Unit: Not Yet Assigned

Filed: October 26, 2000 Examiner: Not Yet Assigned

For: *METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS*

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits an Information Disclosure Statement, including three (3) pages of Form PTO-1449. Most of the documents cited below were cited by or submitted to the Patent Office in Application Serial No. 09/083,307, filed May 22, 1998, to which the present application claims priority. Pursuant to 37 C.F.R. §1.98(d), Applicants are not enclosing copies of these publications. Copies will be provided upon request, however. Copies of the newly cited documents, which are identified with an asterisk (\*), are enclosed.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 01-2507.

**U.S. Patents**

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
4,708,713	11-24-1987	Lentz	604/005
4,486,282	12-04-1984	Bier	204/180P
5,135,919	08-04-1992	Folkman, et al.	514/056

5,147,638	09-15-1992	Esmon, et al.	424/085.8
5,290,807	03-01-1994	Folkman, et al.	514/475
5,523,096	06-04-1996	Okarma, et al.	424/489
5,629,327	05-13-1997	D'Amato	514/323
5,639,725	06-17-1997	O'Reilly, et al.	514/012
5,679,260	10-21-1997	Boos, et al.	210/723
5,698,586	12-16-1997	Kishimoto, et al.	514/475
5,712,291	01-27-1998	D'Amato	514/323
5,713,491	02-03-1998	Hughes, et al.	222/129
5,716,981	02-10-1998	Hunter, et al.	514/449
5,733,876	03-31-1998	O'Reilly, et al.	514/0
5,861,483	01-19-1999	Wolpe	530/385

### Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
43 45 200 A1	12-22-1994	Fresenius AG	DE
196 24 250 A1	01-02-1998	Ahrenholz, et al.	DE

### Publications

\*ANDREWS, et al., "Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin LT) on human T lymphocytes: TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4<sup>+</sup> T cell hybridoma," *J Immunol* 144(7):2582-91 (1990).

\*BONAVIDA, et al., (eds), Tumor Necrosis Factor/Cachecin and Related Cytokines. Int. Conf. Tumor Necrosis Factor and Related Cytotoxins, Heidelberg, 1987, pp. 7-19 (Karger, Basel 1988).

CHEN, et al., "Soluble TNF- $\alpha$  Receptors are constitutively shed and downregulate adhesion molecule expression in malignant gliomas," *J. Neuropathol. Exp. Neurol.* 56(5):541-550 (1997).

COLMAN, et al., Hemostasis and Thrombosis: Basic Principles and Clinical Practice (2nd Ed.), p. 263, J.B.Lippincott:Philadelphia, PA, 1987.

\*FEINMAN, et al., "Tumor necrosis factor is a important mediator of tumor cell killing by human monocytes," *J Immunol* 138(2):635-40 (1987).

\*GATANAGA, et al., "Identification of TNF-LT blocking factor(s) in the serum and ultrafiltrates of human cancer patients," *Lymphokine Res* 9(2):225-29 (1990).

\*HARANAKA & SATOMI, "Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells *in vitro*," *Jpn J Exp Med* 51(3):191-94 (1981).

\*HOWARD, et al., Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family," *Virology* 180(2):633-47 (1991).

JABLONSKA & PEITRUSKA, "Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients," *Arch Immunol Ther Exp (Warsz)*. 45(5-6):449-53 (1997).

\*LANGKOPF & ATZPODIEN, "Soluble tumor necrosis factor receptors as prognostic factors in cancer patients," *Lancet* 344(8914):57-58 (1994).

\*MATHIAS, et al., "Activation of the Sphingomyelin signaling pathway intact EL4 cells and in a cell-free system by IL-1 $\beta$ ," *Science* 259:519-22 (1993).

MATSCHINER, et al., Current Advances in Vitamin K Research, pp. 135-140, (John W. Suttie, ed.) Elsevier Science Publishing Co., Inc., 1988.

\*PHILIP & EPSTEIN, "Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, Gamma-interferon and Interleukin-1," *Nature* 323(6083):86-87 (1986).

\*URBAN, et al., "Tumor necrosis factor: A potent effector molecule for tumor cell killing by activated macrophages," *Proc Natl Acad Sci USA* 83:5233-37 (1986).

\*ZIEGLER-HEITBROCK, et al., "Tumor necrosis factor as effector molecule in monocyte-mediated cytotoxicity," *Cancer Res* 46:5947-52 (1986).

**Remarks**

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst  
Reg. No. 31,284

Dated: October 26, 2000

ARNALL GOLDEN & GREGORY, LLP  
2800 One Atlantic Center  
1201 W. Peachtree Street  
Atlanta, Georgia 30309-3450  
(404) 873-8794  
(404) 873-8795 (fax)